WINDLAS BIOTECH LIMITED
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Strong execution, but insufficient forward visibility and no valuation context for a clean buy call.
Hold: Windlas delivered a strong FY26, with revenue up 19% to ₹9,041 million, reported EBITDA up 11% to ₹1,047 million, PAT up 9% to ₹665 million, and net liquidity of ₹2,507 million.
However, this AGM provided no quantified FY27 guidance or meaningful competitive/analyst challenge; the key near-term catalyst is Plant-6 commercialization in H1 FY27, while reported earnings growth lagged revenue growth.
- Fy26 Results
- Cdmo Growth
- Plant 6
- Injectables
- Exports
- Capital Allocation
Near term
Plant-6 commercialization during H1 FY27 is the principal capacity and growth catalyst.
Monitor whether the injectable facility and Plant-2 extension sustain momentum without weakening margins.
Exports grew 40% to ₹458 million; continued execution in regulated and semi-regulated markets could support incremental growth.
Reported profitability should be watched closely after ₹166 million of non-cash ESOP expense; adjusted EBITDA was ₹1,214 million versus reported EBITDA of ₹1,047 million.
Longer term
Generic Formulations CDMO remains the core growth engine, generating ₹6,637 million of FY26 revenue, up 20%.
Capacity expansion, injectable capabilities and international GMP certifications could improve Windlas’s addressable market over time.
The company’s net-debt-free position, operating cash flow of ₹1,049 million and ROCE/ROE above 25% support continued investment without balance-sheet stress.
Management’s stated focus on customer diversification matters, but the AGM did not quantify customer concentration, retention or wallet-share gains.
Red flags
No numerical FY27 revenue, margin, EPS or cash-flow guidance was provided, limiting the ability to underwrite near-term earnings.
The AGM transcript contains no substantive analyst pushback or detailed competitive Q&A, so claims around customer additions, differentiation and international opportunity remain largely untested.
Revenue rose 19% while reported EBITDA rose 11% and PAT 9%; the sustainability of operating leverage is not yet clear.
Plant-6 commercialization is still an execution milestone rather than delivered capacity, creating timing and ramp-up risk.
The ₹166 million ESOP expense materially separates adjusted from reported profitability; ongoing dilution or compensation costs need monitoring.
Recommendation history
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.